Gain(1)(q21) is an Unfavorable Genetic Prognostic Factor for Patients With Relapsed Multiple Myeloma Treated With Thalidomide but Not for Those Treated With Bortezomib-Reference-Cited by-同舟云学术

Gain(1)(q21) is an Unfavorable Genetic Prognostic Factor for Patients With Relapsed Multiple Myeloma Treated With Thalidomide but Not for Those Treated With Bortezomib

Published:2013-04 Issue:2 Volume:13 Page:123-130
ISSN:2152-2650
Container-title:Clinical Lymphoma Myeloma and Leukemia
language:en
Short-container-title:Clinical Lymphoma Myeloma and Leukemia

Author:

Smetana Jan,Berankova Kristina,Zaoralova Romana,Nemec Pavel,Greslikova Henrieta,Kupska Renata,Mikulasova Aneta,Frohlich Jan,Sevcikova Sabina,Zahradova Lucie,Krejci Marta,Sandecka Viera,Almasi Martina,Kaisarova Petra,Melicharova Hana,Adam Zdenek,Penka Miroslav,Jarkovsky Jiri,Jurczyszyn Arthur,Hajek Roman,Kuglik Petr

Funder

Ministry of Education, Youth and Sports

Czech Science Foundation

Internal Grant Agency of the Ministry of Health

European Union Seventh Framework Program

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference47 articles.

1. Tandem autologous stem cell transplantation in high-risk de novo multiple myeloma: final results of the prospective and randomized IFM 99-04 protocol;Moreau;Blood,2006

2. Prognostic factor analyses of myeloma survival with intergroup trial S9321 (INT 0141): examining whether different variables govern different time segments of survival;Barlogie;Ann Hematol,2011